Sugi Predict

Sugi Predict / Compounds / SCHEMBL4002015

SCHEMBL4002015

SCHEMBL4002015

CN(N)C(=O)c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F7 P08709 1/20 0.58
▸ F3 P13726 1/20 0.58
▸ SARM1 Q6SZW1 1/20 0.58
▸ SIRT2 Q8IXJ6 1/20 0.58
▸ SIRT6 Q8N6T7 1/20 0.58
▸ SIRT1 Q96EB6 1/20 0.58
▸ SIRT3 Q9NTG7 1/20 0.58
▸ SIRT5 Q9NXA8 1/20 0.58
▸ SIRT4 Q9Y6E7 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.55
▸ GAA P10253 2/20 0.55
▸ APP P05067 1/20 0.55
▸ HCAR3 P49019 1/20 0.55
▸ HCAR2 Q8TDS4 1/20 0.55
▸ HDAC1 Q13547 1/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.55
▸ HTT P42858 1/20 0.54
▸ HSD17B10 Q99714 4/20 0.54
▸ TSHR P16473 2/20 0.54
▸ ALOX15 P16050 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161322 0.85 ALDH1A1 (0.59) F7F3SARM1SIRT2SIRT6
SCHEMBL31699264 0.85 ALDH1A1 (0.59) F7F3SARM1SIRT2SIRT6
SCHEMBL6227030 0.85 F7 (0.62) F7F3SARM1SIRT2SIRT6
SCHEMBL29089330 0.83 ALDH1A1 (0.57) F7F3SARM1SIRT2SIRT6
Bromide SCHEMBL6550191 0.83 ALDH1A1 (0.57) F7F3SARM1SIRT2SIRT6
SCHEMBL93651 0.83 ALDH1A1 (0.57) F7F3SARM1SIRT2SIRT6
Iodide SCHEMBL27448062 0.83 ALDH1A1 (0.57) F7F3SARM1SIRT2SIRT6
Hydrochloric Acid SCHEMBL7835171 0.83 ALDH1A1 (0.57) F7F3SARM1SIRT2SIRT6
Hydrogen Peroxide SCHEMBL28248196 0.83 ALDH1A1 (0.62) F7F3SARM1SIRT2SIRT6
SCHEMBL7110271 0.81 ALDH1A1 (0.55) F7F3SARM1SIRT2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612134-A1 DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095005-A1 DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 — — WO disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 — — WO disclosed
EP-3300500-B9 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2021-01-13 — — EP disclosed
CN-108137545-B Triazole agonists of the APJ receptor 美国安进公司 2020-09-22 — — CN disclosed
EP-3300500-B1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-02-26 — — EP disclosed
US-10344016-B2 Bromotriazole intermediates AMGEN INC. (US) 2019-07-09 — — US disclosed
US-20190100510-A1 BROMOTRIAZOLE INTERMEDIATES AMGEN INC. (US) 2019-04-04 — — US disclosed
US-10221162-B2 Triazole agonists of the APJ receptor AMGEN INC. (US) 2019-03-05 — — US disclosed
US-20170037026-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. 2017-02-09 — — US disclosed
WO-2016187308-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2016-11-24 — — WO disclosed
US-20160340336-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. 2016-11-24 — — US disclosed
WO-2016168633-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 — — EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 — — WO disclosed
EP-0126088-A1 ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS E.R. SQUIBB & SONS, INC. (US) 1984-11-28 — — EP disclosed
US-4463015-A Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation E. R. SQUIBB & SONS, INC. (US) 1984-07-31 — — US disclosed
WO-1984000754-A1 ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS SQUIBB & SONS INC (US) 1984-03-01 — — WO disclosed
US-4418076-A 7-Oxabicycloheptane hydrazone prostaglandin analogs useful in treating thrombolytic diseases E. R. SQUIBB & SONS, INC. (US) 1983-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190100510-A1 BROMOTRIAZOLE INTERMEDIATES APH1A, BRDT, APH1B F7 4561/4885F3 4810/4885SARM1 547/4885
US-10344016-B2 Bromotriazole intermediates APH1A, BRDT, APH1B F7 4561/4885F3 4810/4885SARM1 547/4885
US-20170037026-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AGTR1, AGTR2 F7 3107/4885F3 2476/4885SARM1 2472/4885
US-10221162-B2 Triazole agonists of the APJ receptor TBXA2R, AGTR1, AGTR2 F7 3107/4885F3 2476/4885SARM1 2472/4885
US-20160340336-A1 TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AGTR1, AGTR2 F7 3107/4885F3 2476/4885SARM1 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.